2017 Oct 7;390(10103):1664-1675
Hims says GLP-1 services are not available in all 50 states verified during intake
The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity
Retatrutide is being studied in phase 3 clinical trials following promising phase 2 results for weight reduction and metabolic improvement in adults with obesity, but it is not available through NHS prescribing pathways
Future Needs: Better understanding of long-term therapy, ethical considerations in chronic use, pregnancy counseling for teens, and clearer insight into how JAK inhibition interacts with childhood growth